Scimega
- Company typePrivate
- Founded1997
- HeadquartersMontreal, Canada
- Headcount11–50
- GTM typeB2B
- OfferingServices
Scimega firmographics
Firmographics- Name
- Scimega
- Legal name
- Scimega Research Inc.
- Website
- https://scimega.com
- Company type
- Private
- Founded year
- 1997
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Scimega industry classification
Industry- Product category
- Oncology Clinical Research Services (CRO)
- NAICS
- Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Other Scientific and Technical Consulting Services (541690)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)
- akta.pro secondary industries
- Clinical CROs (Phase I–IV) (HLAGAAAA), Patient Recruitment, Site Feasibility & Trial Enablement CROs (HLAGAAAI), Clinical Trial Site Operations & Study Coordination (HLAGACAE)
Keywords
Where Scimega is headquartered
LocationHeadquarters
- HQ city
- Montreal
- HQ country
- Canada
- HQ region
- North America
Offices1 record
Markets served
Scimega business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Oncology Clinical Research Services: Professional services revenue generated through providing oncology clinical trial management services to biotech and biopharma sponsors. Services include site selection, regulatory strategy, clinical monitoring, and country oversight for Phase 1-3 oncology trials in Canada.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Project-based CRO services for oncology clinical trials |
Go-to-market motion3 records
Distribution channels3 records
Marketing channels7 records
Scimega product offering
Product offeringCore offering
Scimega is a niche Contract Research Organization (CRO) providing oncology clinical trial management services exclusively in Canada for biotech and biopharma sponsors. Its core offering pairs the Reverse Feasibility Program - a collaborative platform connecting sponsors with Canada's top performing investigative sites - with site selection, Health Canada regulatory strategy, provincial ethics navigation, clinical monitoring, and country oversight for Phase 1, 2, and 3 oncology trials. The company has completed 100+ oncology trials and has never been rescued by another CRO.
Product overview
Scimega is a niche Canadian oncology CRO founded in 1997 with 29 years of dedicated oncology clinical research experience. The company operates as a single unified service offering centered around the Reverse Feasibility Program, which connects small and mid-sized biopharma companies with a collaborative network of Canada's top performing investigative sites. The core platform is supported by six integrated service modules: Site Selection & Accelerated Study Start-Up, Health Canada Regulatory Strategy, Provincial Ethics Approval Strategy, Clinical Monitoring Services, and Country Oversight. The company specializes exclusively in Phase 1, 2, and 3 oncology clinical trials in Canada, and has never been rescued by another CRO. Scimega delivers 50% faster trial start-up times compared to industry average and maintains 85% source data verification rates.
Differentiator
Problem solved
Functional benefit
Brands
- Reverse Feasibility Program: A collaborative platform connecting Canadian investigative sites with oncology drug developers, featuring a real-time notification system for Canada-wide enrollment opportunities.
- Scimega Network Champions Award
Products and services
- Reverse Feasibility Program Collaborative clinical operations platform that connects a network of Canada's top performing investigative sites with oncology drug developers, providing real-time Canada-wide recruitment notifications and competitive analysis to accelerate oncology trial start-up by 50%.
- Site Selection & Accelerated Study Start-Up Service module leveraging privileged relationships with site contract managers and legal counsel, using pre-negotiated CTA templates and an extensive library of recent contracts and site budgets to expedite first site open and first patient in timelines.
- Health Canada Regulatory Strategy Expert regulatory services evaluating CTA dossier completeness, anticipating Health Canada questions to avoid delays, with a 30-day default approval period and parallel CTA review to ethics and contract processes.
- Provincial Ethics Approval Strategy Navigates centralized provincial research ethics boards (REBs) by leveraging key relationships with centers across Canada to determine optimal provincial or central applicants for faster activation timelines.
- Clinical Monitoring Services Dedicated oncology-focused CRA team providing site-level support from selection to close-out, featuring consistent CRA site assignment strategy and high-quality data collection with 85% SDV rates.
- Country Oversight Project management by Clinical Trial Leaders (CTLs) from site selection through study close-out, including regular internal project reviews, CRA oversight, and direct sponsor liaison for Phase I, II and III oncology trials.
- Early Development Phase 1 & 2 Expertise Specialized expertise in Phase 1 and Phase 2 oncology clinical trials, covering the majority of Scimega's trial portfolio (70% of trials).
- Phase 3 Oncology Clinical Trial Expertise Specialized expertise in Phase 3 oncology clinical trials, delivered as part of Scimega's exclusive Canada-only oncology CRO offering.
Quantifiable outcome
- 50% faster study start-up compared to industry average
- +8 more outcomes
Companies that use Scimega
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles2 records
Scimega technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Scimega partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered minor and core.
- BioQuébecminorScimega joined BioQuébec in 2023 to support Quebec's biotech and life sciences industry. BioQuébec is an industry association representing Quebec's biotechnology and life sciences companies.
- Lean Six SigmacoreScimega officially adopted LEAN methodology as a continuous improvement approach since 2019, working with The Lean Six Sigma Company for professional coaching. The company has a LEAN ambassador who leads improvement projects in collaboration with a professional LEAN coach.
- Society of Quality Assurance (SQA)minorScimega joined the Society of Quality Assurance in 2017, an organization for QA professionals, demonstrating commitment to quality standards and compliance in clinical research.
- Canadian Cancer Research CenterscoreNetwork of over 50 Canadian cancer research centers participating in the Reverse Feasibility Program. These sites have privileged relationships with Scimega and routinely share their academic interests and clinical trial needs to ensure placement of pertinent novel cancer clinical trials.
Scale indicators11 records
Recent moves6 records
Expansion highlights5 records
Scimega competitors and assessment
Company assessmentRegional players
- Altasciences: Altasciences is a Canada-headquartered early-phase CRO offering clinical and bioanalytical services from Canadian facilities. Comparable to Scimega as a fellow Canadian-headquartered CRO serving biotech sponsors, though broader in therapeutic scope and focused on early-phase rather than full oncology programs.
Direct peers
- Medpace: Medpace is a mid-sized, therapeutically-focused CRO with particularly strong oncology capabilities and a reputation for operational excellence. Comparable to Scimega in its focused therapeutic model, full-service offerings, and concentration on small/mid-sized biotech sponsors.
- Worldwide Clinical Trials: Worldwide Clinical Trials is a mid-sized CRO with deep specialization in oncology and other complex therapeutic areas, serving small and mid-sized biopharma. Highly comparable to Scimega in therapeutic focus, customer segment, and emphasis on scientific quality over scale.
- Precision for Medicine: Precision for Medicine is a specialty CRO with dedicated oncology and biomarker-driven trial expertise, serving biotech sponsors. Highly comparable to Scimega in oncology specialization, biomarker/precision medicine focus, and small-to-mid biotech customer base.
- Theradex: Theradex is an oncology-specialty CRO with a long track record in early-phase oncology trials and a reputation for scientific quality. Closely comparable to Scimega in oncology-only focus, early-phase trial emphasis, and full-service oncology offerings for biotech sponsors.
Broad incumbents
- Fortrea (formerly Labcorp Drug Development): Fortrea is a global CRO spun out from Labcorp in 2023, offering full-service oncology clinical research. Comparable to Scimega as a broad incumbent in oncology CRO services, though at substantially greater scale and global reach.
- ICON plc: ICON is one of the world's largest CROs with a full-service oncology offering post-PRA Health Sciences merger. Comparable to Scimega as a competitor for oncology trial contracts, though broader in therapeutic scope, scale, and geographic reach.
- IQVIA: IQVIA is the largest global CRO and clinical technology provider, with extensive oncology capabilities through its IQVIA Biotech and Novella Oncology franchises. Comparable to Scimega as a competitor for oncology trial contracts, particularly for biotech sponsors seeking global reach.
- Parexel: Parexel is a top-5 global CRO with established oncology capabilities, particularly in early-phase and complex trial design. Comparable to Scimega as a broad incumbent competitor targeting small and mid-sized biotech oncology sponsors.
Emerging players
- Veristat: Veristat is a specialized clinical research and biometrics CRO with oncology expertise and a focus on complex, small-to-mid sponsor trials. Comparable to Scimega in therapeutic specialization, customer segment, and emphasis on operational quality for niche oncology programs.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks7 records
Key highlights7 records
Customer concentration
Scimega social profiles
Digital presenceScimega financial estimates
Financial estimateRevenue estimate
Valuation estimate
Scimega leadership team
Management profileNumber of profiles
Profiles4 records
Scimega funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Scimega M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Scimega
What does Scimega do?
Scimega is a niche Contract Research Organization (CRO) providing oncology clinical trial management services exclusively in Canada for biotech and biopharma sponsors. Its core offering pairs the Reverse Feasibility Program - a collaborative platform connecting sponsors with Canada's top performing investigative sites - with site selection, Health Canada regulatory strategy, provincial ethics navigation, clinical monitoring, and country oversight for Phase 1, 2, and 3 oncology trials. The company has completed 100+ oncology trials and has never been rescued by another CRO.
Is Scimega a public or private company?
Scimega is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Scimega founded?
Scimega was founded in 1997. It employs 11 to 50 people.
Where is Scimega based?
Scimega is headquartered in Montreal, Canada, in the North America region.
How does Scimega make money?
One revenue line is on record: oncology Clinical Research Services.
Who are Scimega's main competitors?
Altasciences is listed as a regional player. Direct peers are Medpace, Worldwide Clinical Trials, Precision for Medicine and Theradex. Broad incumbents are Fortrea (formerly Labcorp Drug Development), ICON plc, IQVIA and Parexel. Veristat is listed as an emerging player.
Does Scimega have an API?
No public API is recorded for Scimega.
What industry is Scimega in?
Scimega's product category is Oncology Clinical Research Services (CRO). Its primary akta.pro industry code is HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease), with a secondary code of HLAGAAAA, Clinical CROs (Phase I–IV). Its NAICS code is 5417 and its SIC code is 8731.